IRB Pandemic Impact Report
In this question and answer (Q&A) special report, a dozen IRB administrators, directors, chairs, and other leaders from across the United States were asked about their facilities’ experiences during the COVID-19 pandemic’s early weeks. The leaders responded candidly about their toughest challenges, best new tactics, and how they supported their human research protection community
- Gretchen L. J. Anding, MA, assistant director, UW-Madison Health Sciences IRBs Office, University of Wisconsin
- Cecilia Brooke Cholka, MA, CIP, IRB specialist, University of Nevada, Reno
- Francis J. DiMario, Jr., MD, MA, CIP, professor, pediatrics and neurology, The University of Connecticut; associate chair, academic affairs, department pediatrics; medical director, human research protection program (HRPP); chair of IRB, Connecticut Children’s Medical Center
- Teresa Doksum, PhD, MPH, senior director of quality and research ethics, Abt Associates, Cambridge, MA
- Harry McGee, MPH, SIRB chair, Michigan State University
- Brian Moore, MS, CIP, director, HRPP/IRB, Wake Forest School of Medicine, Clinical Translational Science Institute, Winston-Salem, NC
- Jon Newlin, CIP, assistant director, HRPP, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY
- Linda Reuter, CIP, director, BRANY IRB, Biomedical Research Alliance of New York, Lake Success, NY
- Lisa Rigtrup, operations manager, IRB, University of Utah
- Catherine Rogers, post-approval team manager and senior IRB analyst, UW-Madison Health Sciences IRBs Office
- William Smith, JD, IRB director, Nova Southeastern University, Davie, FL
- Megan Williams, MPA, CIP, director of research administration, academic affairs, Salem State University, Salem, MA
In this question and answer special report, a dozen IRB administrators, directors, chairs, and other leaders from across the United States were asked about their facilities’ experiences during the COVID-19 pandemic’s early weeks.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.